TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01823198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD56-positive CD3-negative Natural Killer Cells
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant
Study: NCT02910973

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Vagus Nerve Stimulation
Description: Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
Study: NCT03411174

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated partial breast irradiation
Description: deliver 40Gy/15Fx to tumor bed areas
Study: NCT04756440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Program and Music Therapy
Description: After the intervention, it is expected that their awareness of Romana cervical cancer will increase, their perception of obstacle towards screening tests will decrease and they will be tested.
Study: NCT03959384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf 80Mg/Ml Intratracheal Suspension
Description: CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ambient Air
Description: Ambient air aspirated in sterile syringes
Study: NCT04474496

Intervention type: OTHER
Intervention: Assessing the impact of COVID-19
Description: Surveying Marshallese adults in the U.S. to determine the impact of COVID-19
Study: NCT04453332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral hormone therapy (estradiol and micronized natural progesterone)
Description: Oral hormone therapy - estradiol 1mg every day and micronized natural progesterone 200mg only 14 days a month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-oral hormone therapy (estradiol and micronized natural progesterone)
Description: Percutaneous estradiol gel 1.5mg every day and micronized progesterone 200mg vaginal only 14 days a month
Study: NCT00236210

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VIP program
Description: Risk assessment, lifestyle counselling, exercise program
Study: NCT04371913

Intervention type: RADIATION
Group type: OTHER
Intervention: 600cGY x 5 fractions
Description: Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using EBRT.
Study: NCT00877760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon a-2a
Description: 180 μg, once per week s.c. for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: 0.5 mg once daily per os, either 72 weeks or 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5 mg once daily per os, either 72 weeks or 96 weeks
Study: NCT00991367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicatrix
Description: Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
Study: NCT02468804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
Study: NCT03228849

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture anchor technique
Description: Suture anchors were used to attach bony fragment. On week 6, patients were then started on physical therapy for 2 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: The injured finger was immobilized in an aluminium splint for 6 weeks. Patients were then started on physical therapy for 2 weeks.
Study: NCT01759693

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling
Study: NCT02094625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: NAC will be administered intravenously over \~60 minutes starting 4 hours following completion of cisplatin chemotherapy.~Three dose levels have been pre-determined:~Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg~Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.~As of August 2018: Dose escalation completed with MTD not reached. Dose level 3 (450mg/kg) selected for expansion with NAC.
Study: NCT01060722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023 (long lasting hGH)
Description: Single subcutaneous dose of MOD-4023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023 (long lasting hGH)
Description: Single subcutaneous dose of MOD-4023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023 (long lasting hGH)
Description: Single subcutaneous dose of MOD-4023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous dose of placebo material

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous dose of placebo material

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous dose of placebo material
Study: NCT00209092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Sequential Therapy: Docetaxel will be given at 100 mg/m\^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m\^2 IV Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Sequential Therapy: Docetaxel will be given at 100 mg/m\^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m\^2 IV Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
Study: NCT00521118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo second curettage
Study: NCT00275041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT00053014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04507490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: 315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: 315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Whole body vibration
Description: 315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration
Study: NCT02568852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined anaesthesia
Description: Laparoscopic cholecystectomy under 10 mmHg pressure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: Laparoscopic cholecystectomy under 10 mmHg pressure
Study: NCT02931747

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are received Placebo once daily for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bacopa Monnieri 300 mg/day
Description: Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bacopa Monnieri 600 mg/day
Description: Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
Study: NCT04339725

Intervention type: OTHER
Intervention: DNA extraction
Description: Extraction fecal DNA and compare disease group to normal group
Study: NCT01355224

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic
Description: Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic
Description: Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
Study: NCT01473355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™ TX
Description: OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
Study: NCT01848795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier Gastrointestinal Liner
Description: Endoscopy placement of EndoBarrier, and clinical and biochemical follow up

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Easy life balloon
Description: Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
Study: NCT03705741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Resistance exercise twice a week during pregnancy week 23-34.
Study: NCT04450004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Vaccine
Description: Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Vaccine
Description: Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Vaccine
Description: Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Vaccine
Description: Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Vaccine
Description: Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Vaccine
Description: Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Vaccine
Description: Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Vaccine
Description: Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Vaccine
Description: Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.
Study: NCT02054663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
Study: NCT01314144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
Study: NCT02928081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Description: Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard lymphadenectomy
Description: Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
Study: NCT00063986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Description: Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Study: NCT02942693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib will be used as induction therapy in experimental arm.
Study: NCT03936712

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing ED (RB) and a caffeine and taurine free beverage drink (PL). All sessions were arranged in the early evening hours to avoid any time of day effects. The two definitive test sessions were separated by an interval of seven days to allow sufficient recovery between tests and to ensure caffeine washout. To avoid identification, two opaque and unmarked cans of RB or PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks were similar in volume, texture, and appearance. One can of RB drink (i.e., 250ml) contained 80 mg of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg vitamin B6 and 487 kJ of energy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drink
Description: The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine, but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate (1 %), supplemented by flavorings, of sodium citrate, acesulfame K, sucralose, potassium sorbate and RB (a flavoring that contains propylene glycol E1520 (0.23 mL).
Study: NCT01345916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 100/6 NEXT DPI® 2 months
Description: CHF 1535 100/6 NEXT DPI® 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 100/6 pMDI 2 months
Description: CHF 1535 100/6 pMDI 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP DPI 2 months
Description: BDP DPI 2 months
Study: NCT04737096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: tDCS
Study: NCT02942693

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Particle Therapy
Description: Same total dose and fractionation will be used in both arms.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Particle Therapy
Description: Same total dose and fractionation will be used in both arms.
Study: NCT01925482

Intervention type: DRUG
Group type: OTHER
Intervention: 6%CO2, 25%O2, balance N2
Description: exposure of middle ear to gas

Intervention type: DRUG
Group type: OTHER
Intervention: 6%CO2, 25%O2, balance N2
Description: exposure of middle ear to gas

Intervention type: DRUG
Group type: OTHER
Intervention: 6% CO2, 0%O2, balance N2
Description: exposure of middle ear to gas
Study: NCT03463408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 240 mg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: 1 mg/kg every 6 weeks
Study: NCT01925482

Intervention type: DRUG
Group type: OTHER
Intervention: 6% CO2, 0%O2, balance N2
Description: exposure of middle ear to gas

Intervention type: DRUG
Group type: OTHER
Intervention: 20%CO2, 6%O2, balance N2
Description: exposure of middle ear to gas

Intervention type: DRUG
Group type: OTHER
Intervention: 20%CO2, 6%O2, balance N2
Description: exposure of middle ear to gas

Intervention type: DRUG
Group type: OTHER
Intervention: 0%CO2, 6%O2, balance N2
Description: exposure of middle ear to gas

Intervention type: DRUG
Group type: OTHER
Intervention: 0%CO2, 6%O2, balance N2
Description: exposure of middle ear to gas

Intervention type: DRUG
Group type: OTHER
Intervention: 6% CO2, 6%O2, balance N2
Description: exposure of middle ear to gas

Intervention type: DRUG
Group type: OTHER
Intervention: 6% CO2, 6%O2, balance N2
Description: exposure of middle ear to gas

Intervention type: DRUG
Group type: OTHER
Intervention: 6%CO2, 6%O2, 0%N2, balance argon
Description: exposure of middle ear to gas

Intervention type: DRUG
Group type: OTHER
Intervention: 6%CO2, 6%O2, 0%N2, balance argon
Description: exposure of middle ear to gas
Study: NCT02382614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiration Valve System